newsfilter
← Latest News
Business Wire·

NeuroPace Highlights Expanding Clinical Evidence Leadership with Published 3-Year Post-Approval Study (PAS) Results in Neurology and NAUTILUS Presentation at AAN 2026

— Published 3-year Post-Approval Study results show 82% median seizure reduction in drug-resistant focal epilepsy — — American Academy of Neurology (AAN) presentation featured 12- and 18-month NAUTILUS data, the first